Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).
We say that because the randomized CABOSUN trial that was conducted on advanced renal cell carcinoma patients who have not been treated before has shown a progression-free survival benefit over standard of care first-line treatment sunitinib. Indeed, the drug demonstrated clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate- or poor-risk RCC.
CABOSUN is a trial being conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis’ collaboration with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The safety data were consistent with those observed in previous studies in patients with advanced RCC and the final results will be submitted for presentation at a future medical conference.
Toni K. Choueiri, M.D., Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and chair of the CABOSUN study said that, “Based on these findings, cabozantinib may have the potential to become a new gold standard for previously untreated patients following their diagnosis with advanced kidney cancer.”
Michael J. Morris, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, and Chair of the Alliance Genitourinary (GU) Committee acknowledged that the Alliance Clinical Trials in Oncology is very gratified to have successfully demonstrated the potential of first-line cabozantinib to benefit patients with renal cell carcinoma in the CABOSUN study.
Exelixis will share the results with regulatory authorities to discuss potential next steps in the development and submission strategy for cabozantinib as a first line treatment of for advanced renal cell carcinoma.
Exelixis is also working closely with clinical advisors on developing a plan for cabozantinib in future clinical trials in other genitourinary malignancies.
Prohost Observations
The possibility that cabozantinib is eligible to become the first-line treatment for advanced RCC, would promises changing the life Exelixis lived during its development stage years. The possibility of approving cabozantinib for other cancers in the urinary and other systems, promises taking the firm to a higher level that hosts only the best accomplishing and revenue-generating firms.
Today’s news is an additional important good news for Exelixis and for EXEL. You surely know what we mean.
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.
Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC
Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).
We say that because the randomized CABOSUN trial that was conducted on advanced renal cell carcinoma patients who have not been treated before has shown a progression-free survival benefit over standard of care first-line treatment sunitinib. Indeed, the drug demonstrated clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate- or poor-risk RCC.
CABOSUN is a trial being conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis’ collaboration with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The safety data were consistent with those observed in previous studies in patients with advanced RCC and the final results will be submitted for presentation at a future medical conference.
Toni K. Choueiri, M.D., Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and chair of the CABOSUN study said that, “Based on these findings, cabozantinib may have the potential to become a new gold standard for previously untreated patients following their diagnosis with advanced kidney cancer.”
Michael J. Morris, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, and Chair of the Alliance Genitourinary (GU) Committee acknowledged that the Alliance Clinical Trials in Oncology is very gratified to have successfully demonstrated the potential of first-line cabozantinib to benefit patients with renal cell carcinoma in the CABOSUN study.
Exelixis will share the results with regulatory authorities to discuss potential next steps in the development and submission strategy for cabozantinib as a first line treatment of for advanced renal cell carcinoma.
Exelixis is also working closely with clinical advisors on developing a plan for cabozantinib in future clinical trials in other genitourinary malignancies.
Prohost Observations
The possibility that cabozantinib is eligible to become the first-line treatment for advanced RCC, would promises changing the life Exelixis lived during its development stage years. The possibility of approving cabozantinib for other cancers in the urinary and other systems, promises taking the firm to a higher level that hosts only the best accomplishing and revenue-generating firms.
Today’s news is an additional important good news for Exelixis and for EXEL. You surely know what we mean.
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.
Other Articles